[go: up one dir, main page]

IN2014DN06567A - - Google Patents

Info

Publication number
IN2014DN06567A
IN2014DN06567A IN6567DEN2014A IN2014DN06567A IN 2014DN06567 A IN2014DN06567 A IN 2014DN06567A IN 6567DEN2014 A IN6567DEN2014 A IN 6567DEN2014A IN 2014DN06567 A IN2014DN06567 A IN 2014DN06567A
Authority
IN
India
Prior art keywords
kinase
inhibitors
compounds
heteroaryl
aryl
Prior art date
Application number
Other languages
English (en)
Inventor
Bang-Chi Chen
Roberto Droghini
Jean Lajeunesse
John D Dimarco
Michael Galella
Ramakrishnan Chidambaram
Original Assignee
Bristol Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Holdings Ireland filed Critical Bristol Myers Squibb Holdings Ireland
Publication of IN2014DN06567A publication Critical patent/IN2014DN06567A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IN6567DEN2014 2004-02-06 2005-02-04 IN2014DN06567A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54249004P 2004-02-06 2004-02-06
US62493704P 2004-11-04 2004-11-04
PCT/US2005/003728 WO2005077945A2 (en) 2004-02-06 2005-02-04 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06567A true IN2014DN06567A (de) 2015-07-10

Family

ID=34864498

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6567DEN2014 IN2014DN06567A (de) 2004-02-06 2005-02-04

Country Status (27)

Country Link
EP (1) EP1711481B2 (de)
JP (2) JP5148115B2 (de)
KR (2) KR101310427B1 (de)
AR (1) AR047533A1 (de)
AT (1) ATE453630T1 (de)
AU (1) AU2005212405B2 (de)
BR (1) BRPI0507476B8 (de)
CA (1) CA2555291C (de)
CY (1) CY1109907T1 (de)
DE (1) DE602005018601D1 (de)
DK (1) DK1711481T4 (de)
ES (1) ES2337272T5 (de)
GE (1) GEP20094804B (de)
HK (1) HK1091835A1 (de)
HR (1) HRP20100166T4 (de)
IL (1) IL177280A (de)
IN (1) IN2014DN06567A (de)
NO (1) NO338049B1 (de)
NZ (1) NZ548613A (de)
PE (1) PE20050691A1 (de)
PL (1) PL1711481T5 (de)
PT (1) PT1711481E (de)
RU (1) RU2382039C2 (de)
SI (1) SI1711481T2 (de)
TW (1) TWI338004B (de)
WO (1) WO2005077945A2 (de)
ZA (1) ZA200606242B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258371A1 (de) 2001-08-10 2010-12-08 Novartis AG Verwendung von c-Src Inhibitoren allein oder in Kombination mit STI571 zur Leukämie Behandlung
ES2386784T3 (es) 2003-05-01 2012-08-30 Bristol-Myers Squibb Company Compuestos de pirazol-amina útiles como inhibidores de quinasas
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
WO2006121742A2 (en) * 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor
EP1919885B1 (de) * 2005-08-05 2010-04-28 Brystol-Myers Squibb Company Herstellung von 2-aminothiazol-5-carbonsäurederivaten
EP1937270A1 (de) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Orale verabreichung von n-(2-chlor-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazol-5-carbonsäureamid und seinen salzen
US20070219370A1 (en) * 2006-03-15 2007-09-20 Bristol-Myers Squibb Company Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof
CA2662580C (en) 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
ES2565521T5 (es) 2007-10-23 2019-12-10 Teva Pharma Polimorfos de dasatinib y proceso para la preparación de los mismos
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) * 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
EP2427452A4 (de) * 2009-05-05 2012-09-26 Merck Sharp & Dohme P38-kinase-hemmende wirkstoffe
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
EP2359813A1 (de) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-(2-chlor-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolcarboxamid
CN102250084A (zh) * 2010-02-08 2011-11-23 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
ES2637829T3 (es) 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
CN102827156A (zh) * 2012-09-11 2012-12-19 湖南欧亚生物有限公司 一种达沙替尼的新的工业合成方法
CN103819469A (zh) * 2012-11-16 2014-05-28 重庆医药工业研究院有限责任公司 一种达沙替尼的晶型及其制备方法
CZ306598B6 (cs) 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
CN103880833B (zh) * 2012-12-19 2018-04-06 北京本草天源药物研究院 达沙替尼一水合物的新晶形及其制备方法和药物组合物
WO2014102759A2 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Process for the preparation of dasatinib and its intermediates
CN103319476B (zh) * 2013-06-13 2015-12-02 济南德爱医药技术有限公司 一种激酶抑制剂
RU2655435C2 (ru) * 2013-07-25 2018-05-29 Басф Се Соли дасатиниба в аморфной форме
KR20160023879A (ko) * 2013-07-25 2016-03-03 바스프 에스이 결정질 형태의 다사티닙 염
CN104341410A (zh) * 2013-08-09 2015-02-11 上海科胜药物研发有限公司 一种达沙替尼新晶型及其制备方法
CN103483289B (zh) * 2013-09-06 2016-01-27 浙江科源化工有限公司 一种2-氨基-n-(2-氯-6-甲基苯基)噻唑-5-甲酰胺的合成方法
WO2015107545A1 (en) 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Water soluble salts of dasatinib hydrate
CZ306732B6 (cs) * 2013-12-19 2017-05-31 Zentiva, K.S. Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu
AU2015200822A1 (en) 2014-03-11 2015-10-01 Cerbios-Pharma Sa Process and intermediates for the preparation of dasatinib
RU2567537C1 (ru) * 2014-04-23 2015-11-10 Олег Ростиславович Михайлов Кристаллическая безводная дельта-модификация n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, способ ее получения и фармацевтическая композиция на ее основе
HU231013B1 (hu) 2014-05-26 2019-11-28 Egis Gyógyszergyár Zrt. Dasatinib sók
WO2017002131A1 (en) * 2015-06-29 2017-01-05 Msn Laboratories Private Limited Crystalline forms of n-(2-chloro-6-methy]phenvn-2-[f6-[4-(2-hvdroxvethvl)-l- piperazinvil-2-methvl-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof
WO2017098391A1 (en) * 2015-12-11 2017-06-15 Shilpa Medicare Limited Process for the preparation of dasatinib
CN105474831B (zh) * 2015-12-16 2017-11-17 湖南省西瓜甜瓜研究所 一种白芨裸种消毒方法
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN105503854A (zh) * 2015-12-31 2016-04-20 哈药集团技术中心 一种达沙替尼无水合物的新晶型物及其制备方法
JP2019504090A (ja) 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド ダサチニブの固体状態形態およびそれらの調製プロセス
WO2017144109A1 (en) 2016-02-25 2017-08-31 Remedica Ltd Dasatinib formulation
CN105830582B (zh) * 2016-04-15 2018-05-01 成都大学 一种白及种子的快速回土培育方法
GB201608587D0 (en) 2016-05-16 2016-06-29 Univ Dundee Treatment of opiod tolerance
CN106117195A (zh) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 一种用于治疗白血病的药物达沙替尼的合成方法
IT201700006145A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
IT201700006157A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
JP6597727B2 (ja) 2017-05-11 2019-10-30 東洋インキＳｃホールディングス株式会社 表面保護用粘着剤および粘着シート
BR112020000302A2 (pt) * 2017-07-07 2020-07-14 Biocon Limited formas polimórficas de dasatinibe
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
TWI764186B (zh) 2018-06-15 2022-05-11 漢達生技醫藥股份有限公司 激酶抑制劑之鹽類及其組合物
EP3643713A1 (de) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclische kinasehemmer und verwendungen davon
CN109369638B (zh) * 2018-11-21 2020-07-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备工艺
CN109503568B (zh) * 2018-12-29 2020-08-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备方法
CN112409349A (zh) * 2019-08-20 2021-02-26 湖南华纳大药厂股份有限公司 激酶抑制剂及其制备、药物组合物和用途
EP4093379A1 (de) 2020-01-24 2022-11-30 Nanocopoeia LLC Amorphe feste dispersionen von dasatinib und deren verwendungen
GB2592680A (en) 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (de) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Mittel und verfahren zur verbesserung des auf den rezeptor gerichteten gentransfers
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN114634421A (zh) * 2022-02-24 2022-06-17 济宁晟泰药业有限公司 一种达沙替尼中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547917A (en) * 1966-12-07 1970-12-15 Uniroyal Inc 2-amino-4-methylthiazole-5-carboxamides
US5514643A (en) * 1993-08-16 1996-05-07 Lucky Ltd. 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
DE602005023587D1 (de) * 2004-01-21 2010-10-28 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
IL177280A0 (en) 2006-12-10
JP2012188446A (ja) 2012-10-04
EP1711481B2 (de) 2013-05-22
IL177280A (en) 2013-09-30
NO20063780L (no) 2006-10-27
NO338049B1 (no) 2016-07-25
CA2555291C (en) 2017-01-17
EP1711481A2 (de) 2006-10-18
HK1091835A1 (en) 2007-01-26
BRPI0507476A (pt) 2007-07-17
KR20120097424A (ko) 2012-09-03
DK1711481T3 (da) 2010-04-19
PL1711481T5 (pl) 2013-10-31
NZ548613A (en) 2010-05-28
SI1711481T2 (sl) 2013-10-30
RU2382039C2 (ru) 2010-02-20
RU2006131591A (ru) 2008-03-20
GEP20094804B (en) 2009-10-26
PE20050691A1 (es) 2005-09-25
PL1711481T3 (pl) 2010-05-31
SI1711481T1 (sl) 2010-03-31
TW200530205A (en) 2005-09-16
CA2555291A1 (en) 2005-08-25
PT1711481E (pt) 2010-02-25
CY1109907T1 (el) 2014-09-10
AU2005212405B2 (en) 2010-08-12
HRP20100166T4 (en) 2013-09-30
ATE453630T1 (de) 2010-01-15
BRPI0507476B8 (pt) 2021-05-25
ES2337272T5 (es) 2013-09-30
JP2007521340A (ja) 2007-08-02
HRP20100166T1 (hr) 2010-05-31
KR101310427B1 (ko) 2013-09-24
ES2337272T3 (es) 2010-04-22
AR047533A1 (es) 2006-01-25
JP5148115B2 (ja) 2013-02-20
AU2005212405A1 (en) 2005-08-25
DE602005018601D1 (de) 2010-02-11
BRPI0507476B1 (pt) 2020-12-08
DK1711481T4 (da) 2013-08-26
WO2005077945A3 (en) 2006-05-18
WO2005077945A2 (en) 2005-08-25
ZA200606242B (en) 2008-01-08
KR20060124692A (ko) 2006-12-05
TWI338004B (en) 2011-03-01
EP1711481B1 (de) 2009-12-30

Similar Documents

Publication Publication Date Title
IN2014DN06567A (de)
WO2006050109A3 (en) Novel kinase inhibitors
WO2007023111A3 (en) P38 map kinase inhibitors and methods for using the same
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2005076990A3 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
EA200870116A1 (ru) Бициклические гетероарильные соединения
ZA200609634B (en) Quinazolinone derivatives useful as vanilloid antagonists
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
TW200621721A (en) Methods of preparing indazole compounds
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
WO2006017054A3 (en) Tricyclic-heteroaryl compounds useful as kinase inhibitors
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
TW200628153A (en) Novel compounds
BRPI0509731A (pt) pirazol[4,3-d]pirimidinas
NO20080160L (no) Mellomprodukter nyttige i syntesene av alkylkinolin og alkylkinazolin kinasemodulatorer og beslektede fremgangsmater for synteser
TW200503722A (en) Substituted 7-aza-quinazoline compounds